Pharmacokinetics and safety of tazarotene.

@article{Menter2000PharmacokineticsAS,
  title={Pharmacokinetics and safety of tazarotene.},
  author={Alan Menter},
  journal={Journal of the American Academy of Dermatology},
  year={2000},
  volume={43 2 Pt 3},
  pages={S31-5}
}
  • Alan Menter
  • Published 2000 in Journal of the American Academy of Dermatology
The pharmacokinetic profile of tazarotene helps to ensure that systemic exposure to the drug and its metabolites is minimal. First, percutaneous penetration is limited, with less than 6% of the applied drug being absorbed into the bloodstream. Second, tazarotene is rapidly metabolized into tazarotenic acid and other metabolites that are not lipophilic. Third, tazarotene and its metabolites are rapidly eliminated from the blood in the urine and feces. These three pharmacokinetic features help to… CONTINUE READING